ADVANCE-HTA has as its fundamental objective, the methodological advancement of HTA across a range of settings in Europe, North and Latin America, among others. This is achieved by involving the wider stakeholder community in the debate surrounding decision-making and resource allocation. In order to achieve this, several complementary streams of research are carried out that address:
- Issues around value for money and the different approaches surrounding current thresholds for decision-making and resource allocation
- The concept of value assessment, and the factors that need to be considered beyond clinical cost effectiveness
- The quality of the evidence required for and the methods associated with the assessment of rare diseases
- Furthering the debate surrounding the elicitation of preferences by deriving these in more realistic settings within the patient community
- The debate on the suitability of current HTA tools across different categories of medical devices (e.g. diagnostics)
- Improving the implementation and capacity building of HTA including beyond Europe, especially where HTA is considered explicitly in decision-making
In undertaking these activities, ADVANCE-HTA aims to broaden the spectrum, complement and address areas of intense methodological debate in the application, use and implementation of HTA across settings. It also aims to improve HTA methods, which can be taken further by competent authorities nationally whilst supplementing the work of supra-national bodies (e.g. EUnetHTA) towards a common understanding of choices in health care decision-making.
ADVANCE-HTA is a three million euro grant funded through the European Commission's Seventh Framework Programme for Research.